Limb bud and heart development protein homolog (LBH)

Limb bud and heart development protein homolog (LBH) is a highly conserved nuclear transcription co-factor that acts downstream of the canonical Wnt/β-catenin signaling pathway. It is classified as an intrinsically disordered protein, allowing it to modulate multiple transcriptional programs by interacting with various partners and target sites. LBH is critical for embryonic development, particularly in limb and heart formation, and is essential for regulating cell proliferation and differentiation via its control of stem cell populations. Aberrant LBH expression plays a crucial role in various cancers, notably breast cancer, hepatocellular carcinoma, gastric cancer, and glioma, where its dysregulation is linked to poor prognosis and enhanced tumor aggressiveness. LBH is also implicated in congenital heart disease and skeletal defects when overexpressed, as seen in partial trisomy 2p syndrome. Therapeutically, LBH is a downstream target of drugs modulating the Wnt/β-catenin pathway, functioning both as a potential diagnostic biomarker for Wnt pathway activation and as a driver of oncogenic processes in multiple cancer types.

Other names

LBHLimb bud and heart development protein homologProtein LBHhLBHLBH regulator of Wnt signaling pathwayLimb bud and heart development homologLBHD1 (paralog)

Drugs such as DKK1 and Wnt7a inhibit canonical Wnt/β-catenin signaling, thereby suppressing LBH expression. β-catenin inhibitors/blockers would be expected to downregulate LBH by interfering with transcriptional activation.